Dataset Information

Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.

ABSTRACT:

Background

This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic.

Methods

A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic.

Results

716 doctors responded effectively with a response rate of 60.1%, and 664 were included in the final analysis. Overall, 51.4% (341/664) of clinicians reported more than a 60% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5% (614/664) of the respondents have been using online medical consultation to substitute for the "face-to-face" visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC.

Discussion

During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.

SUBMITTER: Zhao H

PROVIDER: S-EPMC8312214 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.

Zhao Hong H Zhou Aiping A Zhou Jianguo J Bi Xinyu X Yan Shida S Jin Jing J Wei Wenqiang W Li Muxing M Gong Caifeng C Chen Qichen Q Luo Zhiwen Z Li Ning N Mao Rui R Chen Xiao X Chen Bo B Zheng Rongshou R Zhao Jianjun J Han Yue Y Li Zhiyu Z Che Xu X Tang Yuan Y Sun Yongkun Y Huang Zhen Z Zhang Yefan Y Wang Xiaoying X Zhang Yubao Y Lu Zhenhui Z Dang Xiaowei X Song Tianqiang T Liu Chang C Yue Ping P Yan Dong D Yue Aimin A Zhang Rui R Luo Suxia S Tan Jing J Zhang Xuewen X Bai Xueli X Zhang Xuejun X He Mingyan M Xie Yujun Y Wang Wenling W Yang Po P Yang Yijun Y Zhang Yamin Y Li Qingdong Q Peng Tao T Wang Zusen Z Chen Yajin Y Shang Changzhen C Liang Yingjian Y Zhang Bixiang B Zhang Feng F Wang Liming L Li Duo D Liu Bin B Zhu Xiaofeng X Hu Qinggang Q Chen Minshan M Xiu Dianrong D Xia Feng F Zhang Yanqiao Y Zeng Yong Y Mao Yilei Y Li Xun X Ba Yi Y Liang Tingbo T Shen Feng F Liu Lianxin L Cai Xiujun X Zhou Jian J Cai Jianqiang J

HPB : the official journal of the International Hepato Pancreato Biliary Association 20210726 3

<h4>Background</h4>This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic.<h4>Methods</h4>A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic.<h4>Results</h4>716 doctor ...[more]

PMID: 34400051

Similar Datasets

Project description:The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.

Dataset Information

Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.

Background

Methods

Results

Discussion

Publications

Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets